APP: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of APP. The page also collects GeneMedi's different modalities and formats products for APP in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the APP target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]
| Target ID | GM-T87024 |
| Target Name | APP |
| Gene ID | 351 |
| Gene Official Name | APP |
| Gene Alias | AAA, ABETA, ABPP, AD1I, CTFgamma, CVAP, PN-II, PN2, preA4, APP |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index |
Pre-made APP-specific INN-index biosimilar (antibody&conjugates)-Aducanumab, Solanezumab, Gantenerumab, Bapineuzumab, Ponezumab, Donanemab, Lecanemab, Crenezumab
Anti-APP therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pre-made anti-APP inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-APP benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-APP mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Cat No. | Antibody Name | Format | Classified by tag | Order |
| GM-Tg-hg-T87024-Ab | Anti-APP monoclonal antibody | mab | Biofunctional antibody, Therapeutics Target antibody |  |
Facebook
LinkedIn
Twitter
